GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

February 28, 2013

Conditions
Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Interventions
DRUG

GRN1005

650 mg/m2 IV every 3 weeks

Trial Locations (10)

15232

Univ. of Pittsburgh Medical Center, Pittsburgh

33612

H. Lee Moffitt Cancer Center, Tampa

37203

Tennessee Oncology, Nashville

48201

Karmanos Cancer Institute, Detroit

60426

Ingalls Memorial Hospital, Harvey

60611

Northwestern Univ., Chicago

80045

Univ. Coloardo at Denver, Aurora

92093

Univ. of California San Diego, La Jolla

02215

Dana Farber Cancer Institute, Boston

H2W 1S6

McGill Univ., Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Angiochem Inc

INDUSTRY

NCT01497665 - GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) | Biotech Hunter | Biotech Hunter